Human iPSCs for Elucidating Intercellular Crosstalk Signaling in DCM - Diversity Supplement
人类 iPSC 用于阐明 DCM 中的细胞间串扰信号传导 - 多样性补充
基本信息
- 批准号:10730997
- 负责人:
- 金额:$ 3.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalArrhythmiaBiological AssayCardiacCardiomyopathiesCell LineCellsCensusesClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesComplementDataDilated CardiomyopathyDiseaseDisease modelEthnic OriginFunctional disorderGene ExpressionGeneticHeartHeart DiseasesHispanicHispanic PopulationsHumanIndividualInheritedInvestigationLigandsMethodsModalityOrganoidsParentsPathogenesisPatientsProteomicsReporterSignal PathwaySignal TransductionSystemTechnologyUnited StatesVariantVentricularaptamercardiac tissue engineeringcell typecoronary fibrosisgenome editingheart cellhigh throughput screeninghispanic communityinduced pluripotent stem cellinsightintercellular communicationnovel therapeutic interventionreceptorsingle-cell RNA sequencingsudden cardiac deathtranscriptomics
项目摘要
Summary of Parent R01:
LMNA-related dilated cardiomyopathy (DCM) is among the most prevalent forms of inherited heart disease,
characterized by severe systolic dysfunction and ventricular chamber enlargement. Major hallmarks of
LMNADCM also involve features of non-myocyte dysfunction including myocardial fibrosis and endotheliopathy.
However, precise mechanisms of intercellular communication in the heart remain unclear, in part because the
human cardiac secretome to date has been poorly defined. To overcome this challenge, we propose to leverage
human iPSCs, genome-editing technology, and state-of-the-art omics methods to identify and investigate
crosstalk signaling pathways potentially involved in LMNA-DCM pathogenesis. In Aim 1, we will comprehensively
profile the baseline secretomes of each cell type by employing high-throughput aptamer-based proteomics
methods and perform trans-well co-culture assays to systematically evaluate the downstream functional
consequences of cellular crosstalk. In Aim 2, we will complement these studies with further investigation into
intercellular communication mechanisms in engineered heart tissues (EHTs) of varying LMNA-DCM / control cell
type compositions. The EHTs will be subsequently analyzed by single-cell RNA sequencing (scRNA-seq) to
predict cell-cell crosstalk modalities and construct a list of unique and shared ligand receptor pairs across
conditions. In Aim 3, we will perform large-scale high-throughput screening of >4,000 compounds using
multicellular iPSC-derived cardiac organoid (iPSC-CO) differentiated from tri-lineage reporter lines. We
anticipate that the successful completion of these studies will lead to new mechanistic insight into DCM
pathogenesis and help develop novel therapeutic strategies that can impede and reverse aberrant crosstalk
signaling between cardiac cell types in the diseased heart.
Proposed Supplement:
There are 62.1 million Hispanics living in the United States, according to data from the 2020 United States
Census. In the Hispanic population, heart diseases have been relatively understudied. In this proposed diversity
supplement, we will extend the scope of the parent R01 to include patients from Hispanic ethnicity to investigate
LMNA-related dilated cardiomyopathy (LMNA-DCM. Specifically, in this proposal, we will include 11 individuals
(10 healthy, 1 diseased) from the Hispanic community to expand the diversity of the parent R01. This proposal
will first characterize healthy and diseased Hispanic heart cells derived from induced pluripotent stem cells and
introduce LMNA-DCM variants using CRISPR genome-editing technology to 9 healthy Hispanic cell lines to
validate functional changes between healthy and diseased cells. Then in extended Aim 2, we will generate 3D
Cardiac Organoids using the cell types generated in Aim 1 to capture cell-cell signaling pathways by way of
transcriptomic analysis and gene expression using single-cell RNA sequencing.
家长R01摘要:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lei Stanley Qi其他文献
Lei Stanley Qi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lei Stanley Qi', 18)}}的其他基金
Development of multi-color 3D super-localization LiveFISH and LiveFISH PAINT to investigate the chromatin dynamics at any genomic scale
开发多色 3D 超定位 LiveFISH 和 LiveFISH PAINT,以研究任何基因组规模的染色质动态
- 批准号:
10725002 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Manipulating and Interrogating Spatial Transcriptomics
操纵和询问空间转录组学
- 批准号:
10702050 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
A Cas13d-based screening approach to engineer exhaustion-resistant CAR T cells
基于 Cas13d 的筛选方法来设计抗耗竭 CAR T 细胞
- 批准号:
10431227 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
A Cas13d-based screening approach to engineer exhaustion-resistant CAR T cells
基于 Cas13d 的筛选方法来设计抗耗竭 CAR T 细胞
- 批准号:
10571868 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
High resolution dissection of oncogene enhancer networks via CRISPR screening and live-cell imaging.
通过 CRISPR 筛选和活细胞成像对癌基因增强子网络进行高分辨率解剖。
- 批准号:
10522013 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
Probing relationships between DNA methylation and cellular senescence with high-throughput CRISPR-based epigenetic editing
利用基于 CRISPR 的高通量表观遗传编辑探索 DNA 甲基化与细胞衰老之间的关系
- 批准号:
10593233 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
High resolution dissection of oncogene enhancer networks via CRISPR screening and live-cell imaging.
通过 CRISPR 筛选和活细胞成像对癌基因增强子网络进行高分辨率解剖。
- 批准号:
10671756 - 财政年份:2022
- 资助金额:
$ 3.39万 - 项目类别:
Examining COVID-19 in Down Syndrome Patients Using Human iPSC-Derived Organoids
使用人类 iPSC 衍生的类器官检查唐氏综合症患者的 COVID-19
- 批准号:
10241207 - 财政年份:2021
- 资助金额:
$ 3.39万 - 项目类别:
Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
使用人 iPSC 模拟酪氨酸激酶抑制剂诱导的血管功能障碍
- 批准号:
10518663 - 财政年份:2018
- 资助金额:
$ 3.39万 - 项目类别:
Human iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated Cardiomyopathy
人类 iPSC 用于阐明扩张型心肌病中的细胞间串扰信号传导
- 批准号:
10852761 - 财政年份:2018
- 资助金额:
$ 3.39万 - 项目类别:
相似海外基金
DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
- 批准号:
495592 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
- 批准号:
23K14885 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains
闰盘细胞外纳米结构域调节心律失常的机制
- 批准号:
10668025 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Development of a next-generation telemonitoring system for prognostic prediction of the onset of heart failure and arrhythmia
开发下一代远程监测系统,用于心力衰竭和心律失常发作的预后预测
- 批准号:
23K09597 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of inflammation in the pathogenesis of atrial fibrillation: Implications for atrial remodeling pathophysiology and for early atrial arrhythmia recurrences following radiofrequency ablation and pulsed field ablation
炎症在心房颤动发病机制中的作用:对心房重塑病理生理学以及射频消融和脉冲场消融后早期房性心律失常复发的影响
- 批准号:
514892030 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
WBP Fellowship
Improved arrhythmia ablation via MR-guided robotic catheterization and multimodal clinician feedback
通过 MR 引导的机器人导管插入术和多模式临床医生反馈改善心律失常消融
- 批准号:
10638497 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
- 批准号:
10722857 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility
Ca2 稳态和心律失常易感性的新型调节剂
- 批准号:
10724935 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
Novel Stellate Ganglia Chemo-ablation Approach to Treat Cardiac Arrhythmia and Cardiac Remodeling in Heart Failure
新型星状神经节化疗消融方法治疗心律失常和心力衰竭心脏重塑
- 批准号:
10727929 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 3.39万 - 项目类别:














{{item.name}}会员




